MA31886B1 - Anticorps anti-hepcidine et utilisations de ceux-ci - Google Patents

Anticorps anti-hepcidine et utilisations de ceux-ci

Info

Publication number
MA31886B1
MA31886B1 MA32811A MA32811A MA31886B1 MA 31886 B1 MA31886 B1 MA 31886B1 MA 32811 A MA32811 A MA 32811A MA 32811 A MA32811 A MA 32811A MA 31886 B1 MA31886 B1 MA 31886B1
Authority
MA
Morocco
Prior art keywords
hepcidin
antibodies
humans
hepcidine
counts
Prior art date
Application number
MA32811A
Other languages
Arabic (ar)
English (en)
Inventor
Yuping Anthony Cai
Dennis Patrick Gately
Luhong He
Donmienne Doen Leung
Peng Luan
Barbara Anne Swanson
Ying Tang
Derrick Ryan Witcher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31886(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31886B1 publication Critical patent/MA31886B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des anticorps monoclonaux se fixant sélectivement sur l'hepcidine-25 humaine et se caractérisant par leur forte affinité pour l'hepcidine-25 humaine et leurs fortes propriétés de neutralisation de l'hepcidine mûre. Lesdits anticorps sont thérapeutiquement utiles pour accroître les niveaux de fer sérique, la numération des réticulocytes, la numération des érythrocytes, l'hémoglobine, et/ou les hématocrites chez l'homme et pour le traitement et le diagnostic de troubles médiés par l'hepcidine mûre, tels que l'anémie chez l'homme.
MA32811A 2007-11-02 2010-04-30 Anticorps anti-hepcidine et utilisations de ceux-ci MA31886B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98491007P 2007-11-02 2007-11-02
PCT/US2008/081493 WO2009058797A1 (fr) 2007-11-02 2008-10-29 Anticorps anti-hepcidine et leurs utilisations

Publications (1)

Publication Number Publication Date
MA31886B1 true MA31886B1 (fr) 2010-12-01

Family

ID=40383701

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32811A MA31886B1 (fr) 2007-11-02 2010-04-30 Anticorps anti-hepcidine et utilisations de ceux-ci

Country Status (34)

Country Link
US (3) US7820163B2 (fr)
EP (2) EP2527368B1 (fr)
JP (1) JP5469076B2 (fr)
KR (2) KR20120107145A (fr)
CN (1) CN103492414B (fr)
AR (1) AR069062A1 (fr)
AU (1) AU2008318850B2 (fr)
BR (1) BRPI0819211A2 (fr)
CA (1) CA2704527C (fr)
CL (2) CL2008003190A1 (fr)
CO (1) CO6231037A2 (fr)
CR (1) CR11414A (fr)
CY (1) CY1113630T1 (fr)
DK (1) DK2209806T3 (fr)
DO (2) DOP2010000123A (fr)
EA (1) EA023406B1 (fr)
ES (1) ES2392123T3 (fr)
HR (1) HRP20120870T1 (fr)
IL (1) IL205355A (fr)
JO (1) JO2828B1 (fr)
MA (1) MA31886B1 (fr)
MX (1) MX2010004841A (fr)
MY (1) MY155708A (fr)
NZ (2) NZ584997A (fr)
PE (1) PE20091261A1 (fr)
PL (1) PL2209806T3 (fr)
PT (1) PT2209806E (fr)
RS (1) RS52592B (fr)
SI (1) SI2209806T1 (fr)
TN (1) TN2010000201A1 (fr)
TW (1) TWI409276B (fr)
UA (1) UA98983C2 (fr)
WO (1) WO2009058797A1 (fr)
ZA (1) ZA201003025B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047485A1 (fr) * 2006-10-17 2008-04-24 Naohisa Tomosugi Procédé de diagnostic d'un métabolisme anormal du fer en utilisant de l'hepcidine active en tant qu'indicateur
AR065083A1 (es) 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2008146903A1 (fr) * 2007-05-31 2008-12-04 Naohisa Tomosugi Méthode pour le diagnostic des maladies ischémiques aiguës grâce à l'utilisation d'hepcidine activée en tant que moyen de mesure
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) * 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8609817B2 (en) * 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
BR112012003701A2 (pt) 2009-08-20 2019-09-24 Vifor Int Ag "novos antagonistas de quinolina-hepcidina"
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
WO2011071368A1 (fr) 2009-12-11 2011-06-16 Umc St. Radboud Méthode de mesure de l'hepcidine
CN103154023B (zh) 2010-08-16 2017-04-05 皮里斯制药有限公司 铁调素的结合蛋白
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
US9610356B2 (en) 2011-12-12 2017-04-04 Pieris Pharmaceutical GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
EP2968503B1 (fr) * 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anticorps antihepcidine et leurs utilisations
WO2016049036A1 (fr) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Anticorps anti-hepcidine humanisés et utilisations de ceux-ci
CN104945497B (zh) * 2014-11-21 2018-04-03 南京国龙生物科技有限公司 一种新型抗菌肽Hep‑W及其制备方法和应用
EP3261670A4 (fr) 2015-02-24 2018-08-01 Rpeptide, LLC Anticorps anti-tau
US11203753B2 (en) 2015-03-13 2021-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
TWI789343B (zh) 2016-02-01 2023-01-11 丹麥商碩騰丹麥有限公司 微流體分析系統、執行分析的微流體匣及方法
WO2018234538A1 (fr) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagoniste ou agoniste d'hepcidine destiné à être utilisé dans le traitement d'une dysrégulation du métabolisme du mo et/ou du mn
ES2759622T3 (es) * 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
WO2021222875A1 (fr) 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Procédés d'utilisation d'inhibiteurs d'alk2
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (fr) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Méthodes de traitement d'une surcharge en fer
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en) 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
CA2448382C (fr) 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de l'hepcidine comme regulateur de l'homeostasie ferrique
CN1173737C (zh) 2002-10-21 2004-11-03 钱忠明 Hepcidin(海魄喜定)在制药中的应用
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
JP2007518062A (ja) 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド 敗血症を診断する方法および診断するための組成物
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
WO2006046935A1 (fr) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Procedes permettant d'augmenter l'affinite de liaison des regions variables d'anticorps
WO2006062685A2 (fr) 2004-11-11 2006-06-15 Affymax, Inc. Nouveaux peptides se liant au recepteur de l'erythropoietine
JP5069214B2 (ja) 2005-03-11 2012-11-07 ヴァーミリオン インコーポレイテッド 卵巣癌及び子宮内膜癌のバイオマーカー：ヘプシジン
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8609817B2 (en) * 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof

Also Published As

Publication number Publication date
PE20091261A1 (es) 2009-08-17
JP2011502482A (ja) 2011-01-27
PT2209806E (pt) 2012-10-03
MX2010004841A (es) 2010-07-30
AR069062A1 (es) 2009-12-23
MY155708A (en) 2015-11-13
EA023406B1 (ru) 2016-06-30
WO2009058797A1 (fr) 2009-05-07
US20130164304A1 (en) 2013-06-27
TN2010000201A1 (en) 2011-11-11
US20110027261A1 (en) 2011-02-03
DOP2013000205A (es) 2013-12-15
CL2012001710A1 (es) 2013-04-12
DK2209806T3 (da) 2012-09-17
UA98983C2 (uk) 2012-07-10
US8765129B2 (en) 2014-07-01
JP5469076B2 (ja) 2014-04-09
KR20120107145A (ko) 2012-09-28
CY1113630T1 (el) 2016-06-22
IL205355A0 (en) 2010-12-30
HRP20120870T1 (hr) 2012-11-30
SI2209806T1 (sl) 2012-11-30
NZ584997A (en) 2012-06-29
CA2704527C (fr) 2015-12-15
US8329174B2 (en) 2012-12-11
KR101335059B1 (ko) 2013-12-11
EP2527368A1 (fr) 2012-11-28
ZA201003025B (en) 2011-11-30
BRPI0819211A2 (pt) 2015-06-16
RS52592B (sr) 2013-04-30
ES2392123T3 (es) 2012-12-04
PL2209806T3 (pl) 2013-01-31
EP2527368B1 (fr) 2016-08-24
US7820163B2 (en) 2010-10-26
CA2704527A1 (fr) 2009-05-07
CR11414A (es) 2010-08-05
KR20100067682A (ko) 2010-06-21
EP2209806B1 (fr) 2012-08-22
AU2008318850A1 (en) 2009-05-07
CN103492414A (zh) 2014-01-01
US20090136495A1 (en) 2009-05-28
JO2828B1 (en) 2014-09-15
CO6231037A2 (es) 2010-12-20
CN103492414B (zh) 2016-04-13
HK1142341A1 (en) 2010-12-03
AU2008318850B2 (en) 2014-05-29
DOP2010000123A (es) 2010-08-15
IL205355A (en) 2015-05-31
EP2209806A1 (fr) 2010-07-28
NZ598391A (en) 2013-07-26
CL2008003190A1 (es) 2009-09-04
EA201070553A1 (ru) 2010-10-29
TW200927759A (en) 2009-07-01
TWI409276B (zh) 2013-09-21

Similar Documents

Publication Publication Date Title
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
MA30337B1 (fr) Anticorps
MX2022012685A (es) Compuestos específicos contra la proteína s de coronavirus y usos de los mismos.
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
WO2005110474A3 (fr) ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
WO2004019878A3 (fr) Adzymes et leurs utilisations
MA37670A1 (fr) Anticorps anti-transglutaminase 2
ATE466886T1 (de) Adzyme und deren verwendungen
MA34979B1 (fr) Molecules de liaisonbispecifiques se liant a vegf et ang2
EP2502999A3 (fr) Procédés et compositions pour traiter et détecter des maladies à médiation par SOD1 à mauvais repliement
MA38161A1 (fr) Anticorps anti-bmp-6
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MA31838B1 (fr) Anticorps se liant à l'il-4 et/ou à l'il-3 et leurs utilisations
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
EA201201067A1 (ru) Способ получения связывающей молекулы, специфичной к белку, ассоциированному с расстройством, или антитела, или его связывающего фрагмента, или по меньшей мере одной цепи иммуноглобулина, связывающих вышеуказанный белок (варианты), связывающая молекула, антитело, цепь иммуноглобулина или их связывающий фрагмент (варианты), полинуклеотид, вектор и клетка-хозяина, их включающая композиция
MA33279B1 (fr) Compositions et procédés pour l'augmentation de la croissance des muscles
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof